drugset / Trial / NCT00024414

DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer

NCT00024414

Phase 2 Unknown Theradex
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

Timeline

Start
2001-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject PACLITAXEL DOCOSAHEXAENOIC ACID Small molecule Intravenous

Indications